RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood cancers: early trial of SG301 begins
Disease control OngoingThis early-stage trial tests a new drug called SG301 in 61 people with blood cancers like multiple myeloma that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps control the cancer. P…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:26 UTC
-
New manufacturing process for myeloma drug tested in 108 patients
Disease control OngoingThis study tests whether a new way of making teclistamab works as well as the current version in people with multiple myeloma that has come back or not responded to treatment. About 108 participants will receive either the old or new version of the drug to compare how the body pr…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Last-Resort myeloma drug made available before approval
Disease control NO_LONGER_AVAILABLEThis program offered early access to talquetamab, an investigational drug, for people with multiple myeloma that had stopped responding to other treatments. It was designed for patients who had no other options and whose doctors requested the drug on their behalf. The program is …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New immunotherapy shows promise in battling Hard-to-Treat multiple myeloma
Disease control OngoingThis study tests a new drug called teclistamab against two standard treatment combinations (PVd or Kd) in about 614 people with multiple myeloma that has come back or not responded after 1 to 3 prior therapies. The goal is to see if teclistamab can better delay cancer progression…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo therapy aims to control relapsed blood cancer
Disease control OngoingThis study tests whether adding the drug talquetamab to standard treatments can help people with multiple myeloma (a blood cancer) whose cancer has returned or stopped responding to prior therapy. About 864 participants will receive one of three treatment combinations. The main g…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New hope for Tough-to-Treat myeloma: Three-Drug combo under trial
Disease control OngoingThis phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has come back or stopped responding to treatment. About 606 participants will be randomly assigned to r…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New hope for Hard-to-Treat myeloma patients through expanded access program
Disease control APPROVED_FOR_MARKETINGThis program gives talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all available treatments and cannot join a clinical trial. The goal is to provide access to this therapy before it is fully…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 06, 2026 16:02 UTC